Relationship between Darbepoetin and Intermittent Hypoxemia in Preterm Infants.
OBJECTIVE: In the Darbepoetin to Improve Red Cell Mass and Neuroprotection in Preterm Infants Trial (Darbe; NCT03169881), infants <29wks gestation receiving darbepoetin were less likely to develop bronchopulmonary dysplasia (BPD) and had higher hematocrit and red blood cell counts (RBC) suggesting that darbepoetin may augment tissue oxygen delivery and thereby improve respiratory outcomes. Intermittent hypoxemia (IH) is associated with an increased risk of BPD, and it is possible that darbepoetin reduces BPD by attenuating IH. STUDY DESIGN: A subcohort of 94 infants enrolled in Darbe were retrospectively analyzed. Number, duration, nadir and total time with IH <90% and <80% were identified through 42 days of age on continuous oxygen saturation recordings. Hematocrit and RBC counts were documented at days 14 and 42. RESULTS: Darbepoetin infants had a higher hematocrit at day 42 and there were fewer IH events <80% with a higher hematocrit (β=-1.51, 95% CI (-2.67, -0.36), p=0.03). However, the effect of darbepoetin supplementation on patterns of IH was limited to a significantly higher nadir (less severe) for IH <80% (β=-0.02, 95% CI (-0.04, 0), p=0.04). CONCLUSIONS: Darbepoetin increases hematocrit but only modestly improves oxygen stability in preterm infants.
Authors
- Juliann Marie Di Fiore
- Namasivayam Ambalavanan (ORCID: https://orcid.org/0000-0003-0731-9092)
- Anna Maria Hibbs (ORCID: https://orcid.org/0000-0001-6773-068X)
- Nori Mercuri Minich (ORCID: https://orcid.org/0000-0001-5448-220X)
- Richard J Martin
- Yuxi Zhu
Publication Details
- Journal
- PubMed
- Published
- 2026-11-13
- DOI
- https://doi.org/10.1159/neo/adsag043
- Primary Topic
- Neonatal Respiratory Health Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00